LLY vs MANE
Eli Lilly and Company vs Veradermics, Incorporated — AI-powered side-by-side comparison
LLY
Eli Lilly and Company
68
Buy
VS
MANE
Veradermics, Incorporated
71
Buy
| Metric | LLY | MANE |
|---|
| AI Score |
68
|
71
|
| Price |
$1,180.33
|
$112.65
|
| P/E Ratio |
39.54×
|
-52.67×
|
| ROE |
77.8%
|
57.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
84.0%
|
0.0%
|
| Debt / Equity |
1.62×
|
0.00×
|
| Dividend Yield |
0.6%
|
0.0%
|
| RSI (14) |
57.1
|
56.7
|
| Beta |
0.506
|
1.3492
|
| Expected Upside |
+5.8%
|
+3.2%
|
AI Committee View
Current Innellis committee reasoning for LLY versus MANE.
MANE leads by 3 points.
MANE scores 71/100 (Buy) versus LLY at 68/100 (Buy).
LLY Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
MANE Committee View
80% agreement
5 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Risk/reward is unfavorable: 22.3% downside vs 3.2% upside.